 |
|
|
|
 |
|
|
| Article 1 to 10 out of 32 concerning Wyeth
|
-
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
(21 Jan 2010)
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia ...
-
Wyeth Pharmaceuticals initiates Phase II and pays Ablynx another milestone in the TNF-alpha Nanobody collaboration
(02 Oct 2009)
Ablynx announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 million has been triggered by the initiation by Wyeth of a first Phase II ...
-
Biotie Reaches Milestone in Wyeth Collaboration
(31 Aug 2009)
Biotie announced that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.Timo Veromaa, President and ...
-
Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth
(21 Jul 2009)
Pfizer Inc announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Wyeth. The Commission's decision includes Pfizer’s commitment to divest certain animal health ...
-
Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women
(30 Apr 2009)
Wyeth Pharmaceuticals, a division of Wyeth, announced that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis ...
-
Pfizer to Acquire Wyeth
(27 Jan 2009)
Pfizer and Wyeth announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. The Boards of ...
-
Crucell and Wyeth in discussion on a combination of the two companies
(09 Jan 2009)
Crucell N.V. confirmed that it is in friendly discussions with Wyeth that may lead to a combination of the two companies. These discussions are at a preliminary stage and there is no certainty that they will result in a transaction. An update will ...
-
Ablynx reaches milestone in TNF-alpha nanobody collaboration with Wyeth Pharmaceuticals
(17 Dec 2008)
Ablynx announced that it has reached a milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $3 million has been triggered by the initiation by Wyeth of a first Phase I study in ...
-
Global Vaccine Market Forecast to 2012
(09 Oct 2008)
Examine This Global Vaccine Market Forecast to 2012 as the Market is Expected to Emerge as the Fastest Growing Therapy Area in the Next 5 Years
Research and Markets has announced the addition of the "Global Vaccine Market Forecast to 2012" report to their offering."Global Vaccine Market Forecast to 2012”, our new research report, states that vaccines, which were earlier thought as a low ...
-
Dyax Corp. Announces First Market Approval from Licensing and Funded Research Program
(03 Mar 2008)
Peptide ligand used in purification process during manufacture of Wyeth's XYNTHA
Dyax Corp. announced that Wyeth Pharmaceuticals, a division of Wyeth, recently received market approval from the U.S. Food and Drug Administration for XYNTHA(TM) (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free), a recombinant factor VIII ...
Additional information
Wyeth
Madison, NJ, USA
Company
|
|
|
|
|
|
Top
